Clinical impact of breakpoint position within M-bcr in chronic myeloid leukemia. 1993

T Fioretos, and P G Nilsson, and P Aman, and S Heim, and U Kristoffersson, and C Malm, and B Simonsson, and I Turesson, and F Mitelman
Department of Clinical Genetics, Lund University Hospital, Sweden.

We have analyzed the M-bcr breakpoint position in 133 Philadelphia-positive chronic myeloid leukemia patients and correlated the findings with clinical, hematologic, and cytogenetic data. We also investigated the splicing pattern of the BCR-ABL mRNA in 30 patients, using reverse transcriptase PCR. No statistically significant differences were found between breakpoint position within M-bcr and clinical parameters at diagnosis, the karyotypic evolution pattern, or the leukemic phenotype during blast crisis. Furthermore, the breakpoint position within M-bcr did not correlate with the duration of chronic phase or survival time. When the splicing pattern of the BCR-ABL mRNA was compared with the results of the genomic breakpoint mapping, it was found that approximately 60% (8/14) of the patients with a 5' break expressed b2a2 fusion mRNA, whereas all patients (10/10) with a 3' break expressed b3a2 BCR-ABL mRNA.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D011505 Protein-Tyrosine Kinases Protein kinases that catalyze the PHOSPHORYLATION of TYROSINE residues in proteins with ATP or other nucleotides as phosphate donors. Tyrosine Protein Kinase,Tyrosine-Specific Protein Kinase,Protein-Tyrosine Kinase,Tyrosine Kinase,Tyrosine Protein Kinases,Tyrosine-Specific Protein Kinases,Tyrosylprotein Kinase,Kinase, Protein-Tyrosine,Kinase, Tyrosine,Kinase, Tyrosine Protein,Kinase, Tyrosine-Specific Protein,Kinase, Tyrosylprotein,Kinases, Protein-Tyrosine,Kinases, Tyrosine Protein,Kinases, Tyrosine-Specific Protein,Protein Kinase, Tyrosine-Specific,Protein Kinases, Tyrosine,Protein Kinases, Tyrosine-Specific,Protein Tyrosine Kinase,Protein Tyrosine Kinases,Tyrosine Specific Protein Kinase,Tyrosine Specific Protein Kinases
D011518 Proto-Oncogene Proteins Products of proto-oncogenes. Normally they do not have oncogenic or transforming properties, but are involved in the regulation or differentiation of cell growth. They often have protein kinase activity. Cellular Proto-Oncogene Proteins,c-onc Proteins,Proto Oncogene Proteins, Cellular,Proto-Oncogene Products, Cellular,Cellular Proto Oncogene Proteins,Cellular Proto-Oncogene Products,Proto Oncogene Products, Cellular,Proto Oncogene Proteins,Proto-Oncogene Proteins, Cellular,c onc Proteins
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002873 Chromosome Fragility Susceptibility of chromosomes to breakage leading to translocation; CHROMOSOME INVERSION; SEQUENCE DELETION; or other CHROMOSOME BREAKAGE related aberrations. Chromosomal Fragility,Fragility, Chromosomal,Fragility, Chromosome
D002874 Chromosome Mapping Any method used for determining the location of and relative distances between genes on a chromosome. Gene Mapping,Linkage Mapping,Genome Mapping,Chromosome Mappings,Gene Mappings,Genome Mappings,Linkage Mappings,Mapping, Chromosome,Mapping, Gene,Mapping, Genome,Mapping, Linkage,Mappings, Chromosome,Mappings, Gene,Mappings, Genome,Mappings, Linkage
D002892 Chromosomes, Human, Pair 22 A specific pair of GROUP G CHROMOSOMES of the human chromosome classification. Chromosome 22
D005260 Female Females

Related Publications

T Fioretos, and P G Nilsson, and P Aman, and S Heim, and U Kristoffersson, and C Malm, and B Simonsson, and I Turesson, and F Mitelman
June 1992, Blood,
T Fioretos, and P G Nilsson, and P Aman, and S Heim, and U Kristoffersson, and C Malm, and B Simonsson, and I Turesson, and F Mitelman
August 1996, Leukemia & lymphoma,
T Fioretos, and P G Nilsson, and P Aman, and S Heim, and U Kristoffersson, and C Malm, and B Simonsson, and I Turesson, and F Mitelman
March 2013, Medical oncology (Northwood, London, England),
T Fioretos, and P G Nilsson, and P Aman, and S Heim, and U Kristoffersson, and C Malm, and B Simonsson, and I Turesson, and F Mitelman
January 1990, British journal of haematology,
T Fioretos, and P G Nilsson, and P Aman, and S Heim, and U Kristoffersson, and C Malm, and B Simonsson, and I Turesson, and F Mitelman
May 1992, Blood,
T Fioretos, and P G Nilsson, and P Aman, and S Heim, and U Kristoffersson, and C Malm, and B Simonsson, and I Turesson, and F Mitelman
December 1990, Blood,
T Fioretos, and P G Nilsson, and P Aman, and S Heim, and U Kristoffersson, and C Malm, and B Simonsson, and I Turesson, and F Mitelman
January 1992, Acta haematologica,
T Fioretos, and P G Nilsson, and P Aman, and S Heim, and U Kristoffersson, and C Malm, and B Simonsson, and I Turesson, and F Mitelman
January 1992, Haematologica,
T Fioretos, and P G Nilsson, and P Aman, and S Heim, and U Kristoffersson, and C Malm, and B Simonsson, and I Turesson, and F Mitelman
October 1994, Leukemia,
T Fioretos, and P G Nilsson, and P Aman, and S Heim, and U Kristoffersson, and C Malm, and B Simonsson, and I Turesson, and F Mitelman
September 1991, Blood,
Copied contents to your clipboard!